Bisphosphonates used in malignant disease (Formulary)

PAMIDRONATE DISODIUM

Important: Therapy notes


Risk minimisation materials

Important: Formulation and dosage details

Formulation:

Dry powder and solvent for solution for infusion 15mg, 90mg (specialist use only)

DENOSUMAB

Important: Therapy notes

MHRA advice: Denosumab (Xgeva) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation (June 2018) (www.gov.uk).
MHRA advice: 
Denosumab (Prolia, Xgeva): reports of osteonecrosis of the external auditory canal (June 2017) (www.gov.uk).
MHRA advice: Denosumab (Xgeva, Prolia): intravenous bisphosphonates: osteonecrosis of the jaw - further measures to minimise risk (July 2015) (www.gov.uk).

Important: Formulation and dosage details

Formulation:

Solution for injection (Xgeva®) 120mg/1·7mL (specialist use only)

Dosage:

See SMC advice 651/10.

IBANDRONIC ACID

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 50mg, 150mg (specialist use only)

SODIUM CLODRONATE

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 800mg (specialist use only)

ZOLEDRONIC ACID

Important: Therapy notes

For reduction of bone damage in advanced malignancies involving bone and hypercalcaemia of malignancy.

Risk minimisation materials

Important: Formulation and dosage details

Formulation:

Solution for infusion 4mg/5mL (specialist use only)

Editorial Information

Document Id: F187